Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer

Current Treatment Options in Oncology

Volumn 7, Issue 5, 2006, Pages 381-388

  Keedy, Vicki L ^a   Berlin, Jordan ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; STREPTOZOCIN;

ABDOMINAL ABSCESS; ABDOMINAL BLEEDING; ANASTOMOSIS LEAKAGE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS FISTULA; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 33748339529     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0006-9     Document Type: Review

References (27)

1. Yang GY, Wagner TD, Fuss M, Thomas CR Jr: Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005, 55:352-367.
2. Kim J, Czischke K, Brennan M, Conlon K: Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 2002, 6:763-769.
3. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
4. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776-784.
6. Neoptolemos JP, Kerr DJ, Beger H, et al.: ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997, 58:570-577.
7. Abrams RA, Lillemoe KD, Plantadosi S: Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001, 358:1565-1566.
8. Stocken DD, Buchler MW, Dervenis C, et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381.
9. Neuhaus P, Oettle H, Post S, et al.: A randomised, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer. Proc Am Soc Clin Oncol 2005, 23:4015.
10. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreatico-duodenectomy for pancreatic adenocarcinoma. Am J Surg 2003, 185:476-480.
11. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005, 23: 1.
12. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004, 22:2610-2616.
13. Kindler Hl, Friberg G, Singh DA, et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
14. Yeo C, Cameron J, Sohn T, et al.: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997, 226:248-257.
15. Willett C, Lewandrowski K, Warshaw A, et al.: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993, 217:144-148.
16. Moutardier V, Turrini O, Huiart L, et al.: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg 2004, 8:502-510.
17. Sasson AR, Wetherington RW, Joffman JP, et al.: Neo-adjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 2003, 34:121-128.
18. Hoffman J, Lipsits S, Pisansky T, et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, respectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:317-323.
19. Pisters P, Wolff R, Janjan N, et al.: Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002, 20:2537-2544.
20. Magnin V, Moutardier V, Giovannini M, et al.: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 55:1300-1304.
21. White R, Tyler D: Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am 2004, 13:675-684.
22. Snady H, Bruckner H, Cooperman A, et al.: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. Cancer 2000, 89:314-327.
23. Pipas J, Barth R, Zaki B, et al.: Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005, 12:995-1004.
24. Ammori J, Colletti L, Zalupski M, et al.: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003, 7:766-772.
25. Kastl S, Brunner T, Hermann O, et al.: Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur J Surg Oncol 2000, 26:578-582.
26. Cheng T, Sheth K, White R: Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 2005, 13:66-74.
27. Hoffman J, McGinn C, Szarka C, et al.: A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998, 17:1090.